Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

[Anti-rheumatic effect of JAK-inhibitors].

Yamaoka K, Maeshima K, Kubo S, Sonomoto K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(2):112-7. Japanese.

2.

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

Yamaoka K, Tanaka Y.

Expert Opin Pharmacother. 2014 Jan;15(1):103-13. doi: 10.1517/14656566.2014.854771. Review.

PMID:
24188100
3.

[JAK inhibitor].

Yamaoka K, Tanaka Y.

Nihon Rinsho. 2013 Jul;71(7):1243-7. Review. Japanese.

PMID:
23961674
4.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142
5.

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318-28. Review.

6.

[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].

Varisco PA, So A.

Rev Med Suisse. 2014 Jan 22;10(414):187-91. French.

PMID:
24624736
7.

Tofacitinib for treatment of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Adv Ther. 2013 Aug;30(8):713-26. doi: 10.1007/s12325-013-0047-y. Review.

PMID:
23943546
8.

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.

Vyas D, O'Dell KM, Bandy JL, Boyce EG.

Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790. Review.

PMID:
24285764
9.

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.

Tanaka Y, Yamaoka K.

Mod Rheumatol. 2013 May;23(3):415-24. doi: 10.1007/s10165-012-0799-2. Review.

PMID:
23212593
10.

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS.

Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028.

11.

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.

Tanaka Y.

J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Review.

PMID:
26152731
12.

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y.

Rheumatology (Oxford). 2014 May;53(5):914-8. doi: 10.1093/rheumatology/ket466.

13.

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

MacFarlane LA, Todd DJ.

Int J Rheum Dis. 2014 May;17(4):359-68. doi: 10.1111/1756-185X.12293. Review.

PMID:
24460872
14.

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.

Garber K.

Nat Biotechnol. 2013 Jan;31(1):3-4. doi: 10.1038/nbt0113-3. No abstract available.

PMID:
23302910
15.

Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.

Vuitton L, Koch S, Peyrin-Biroulet L.

Curr Drug Targets. 2013 Nov;14(12):1385-91. Review.

PMID:
23627915
16.

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y.

Arthritis Rheum. 2012 Jun;64(6):1790-8. doi: 10.1002/art.34329.

17.

Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.

Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, Sakai T, Nakamura M, Motokawa S, Nakamura T, Kawakami A.

Clin Exp Immunol. 2014 Feb;175(2):208-14. doi: 10.1111/cei.12234.

18.

Tofacitinib for the treatment of moderate-to-severe psoriasis.

Chiricozzi A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, Chimenti MS.

Expert Rev Clin Immunol. 2015 Apr;11(4):443-55. doi: 10.1586/1744666X.2015.1013534. Review.

PMID:
25666451
19.

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.

Bannwarth B, Kostine M, Poursac N.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):753-61. doi: 10.1517/17425255.2013.789500. Review.

PMID:
23570265
Items per page

Supplemental Content

Support Center